Clinical Trial Update: Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for TSHA-102 gene therapy in young girls with Rett syndrome, focusing on safety and preliminary efficacy, with the study currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• TSHA-102

Snippet

Sponsor: Taysha Gene Therapies, Inc. | Conditions: Rett Syndrome | Phase 3 | Status: NOT_YET_RECRUITING